MedTrace Logo

Pilot Study to Evaluate the Plasma Profile of Revifast

NCT04258306 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-04-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate in 6 subjects aged between 18 and 60 years the peak blood (plasma profile) of two formulations, indistinguishable from each other, containing:

A) 180 mg natural Resveratrol (Polygonum cuspidatum 98%) B) 180 mg of Revifast® (resveratrol from supported on Magnesium hydroxide).

Conditions

  • Nutrient; Excess
  • Product Use Issue

Interventions

DIETARY_SUPPLEMENT

Revifast

Revifast® is based on natural resveratrol supported on Magnesium hydroxide. Revifast® particles confer an improved dissolution rate in tests that mimic the gastric environment compared to Polygonum cuspidatum resveratrol (98%).

DIETARY_SUPPLEMENT

pure resveratrol

resveratrol extracted from Polygonum cuspidatum resveratrol (98%).

Sponsors & Collaborators

  • Bernard Fioretti

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2017-11-20
Completion
2019-04-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04258306 on ClinicalTrials.gov